Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Iovance Biotherapeutics (IOVA) Invested Capital (2016 - 2025)

Historic Invested Capital for Iovance Biotherapeutics (IOVA) over the last 14 years, with Q3 2025 value amounting to $702.3 million.

  • Iovance Biotherapeutics' Invested Capital fell 920.13% to $702.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $702.3 million, marking a year-over-year decrease of 920.13%. This contributed to the annual value of $710.4 million for FY2024, which is 2151.71% up from last year.
  • As of Q3 2025, Iovance Biotherapeutics' Invested Capital stood at $702.3 million, which was down 920.13% from $698.5 million recorded in Q2 2025.
  • In the past 5 years, Iovance Biotherapeutics' Invested Capital registered a high of $773.5 million during Q3 2024, and its lowest value of $578.6 million during Q2 2023.
  • Its 3-year average for Invested Capital is $691.4 million, with a median of $698.5 million in 2025.
  • In the last 5 years, Iovance Biotherapeutics' Invested Capital skyrocketed by 3283.46% in 2024 and then plummeted by 920.13% in 2025.
  • Over the past 3 years, Iovance Biotherapeutics' Invested Capital (Quarter) stood at $584.6 million in 2023, then rose by 21.52% to $710.4 million in 2024, then decreased by 1.14% to $702.3 million in 2025.
  • Its Invested Capital was $702.3 million in Q3 2025, compared to $698.5 million in Q2 2025 and $767.9 million in Q1 2025.